Literature DB >> 30199470

Direct and Indirect Costs Among United States Commercially Insured Employees With Migraine.

Adrienne M Gilligan1, Shonda A Foster, Amy Sainski-Nguyen, Robert Sedgley, David Smith, Paula Morrow.   

Abstract

OBJECTIVE: The aim of this study was to compare direct, indirect, and societal (direct plus indirect) costs between patients with and without migraine (controls).
METHODS: Patients with migraine were identified from MarketScan claims and Health and Productivity Management databases from January 1, 2010, to December 31, 2013, and were propensity score matched (1:1) to controls.
RESULTS: Patients with migraine (N = 26,647) were matched to controls, of whom 4323 were matched for work absence and 26,212 for short-term disability eligibility. Mean annualized direct costs ($13,032 vs $3234), indirect costs due to absence ($4104 vs $3531) and short-term disability ($1131 vs $52), and societal costs due to absence ($16,043 vs $6938) and short-term disability ($14,278 vs $3182) were all significantly higher (P < 0.001) for those patients with migraine versus controls, respectively.
CONCLUSION: Migraine imposes high direct and indirect economic burden on payers and society due to significantly higher work productivity loss than controls.

Entities:  

Mesh:

Year:  2018        PMID: 30199470     DOI: 10.1097/JOM.0000000000001450

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  8 in total

1.  Average lost work productivity due to non-fatal injuries by type in the USA.

Authors:  Cora Peterson; Likang Xu; Sarah Beth L Barnett
Journal:  Inj Prev       Date:  2020-05-04       Impact factor: 2.399

2.  Migraine comorbidity and cognitive performance in patients with focal epilepsy.

Authors:  Olivia A J Begasse de Dhaem; Jacqueline French; Chris Morrison; Kimford J Meador; Dale C Hesdorffer; Sabrina Cristofaro; Mia T Minen
Journal:  Epilepsy Behav       Date:  2019-06-07       Impact factor: 2.937

3.  Health Care Utilization and Costs in Patients With Migraine Who Have Failed Previous Preventive Treatments.

Authors:  Lawrence Newman; Pamela Vo; Lujia Zhou; Cristina Lopez Lopez; Andy Cheadle; Melvin Olson; Juanzhi Fang
Journal:  Neurol Clin Pract       Date:  2021-06

4.  Migraine and the risk of dementia: a meta-analysis and systematic review.

Authors:  Wei Jiang; Guo-Hua Liang; Jia-Ai Li; Peng Yu; Ming Dong
Journal:  Aging Clin Exp Res       Date:  2022-01-31       Impact factor: 3.636

5.  Real-world assessment of the relationship between migraine-related disability and healthcare costs in the United States.

Authors:  Linda Harris; Gilbert L'Italien; Anil Kumar; Prafullakumar Seelam; Chris LaVallee; Vladimir Coric; Richard B Lipton
Journal:  Headache       Date:  2022-03-28       Impact factor: 5.311

6.  Trends in utilization and costs of migraine medications, 2017-2020.

Authors:  Jennifer L Nguyen; Kiraat Munshi; Samuel K Peasah; Elizabeth C S Swart; Monal Kohli; Rochelle Henderson; Chester B Good
Journal:  J Headache Pain       Date:  2022-08-28       Impact factor: 8.588

7.  Impact of migraine on health care utilization and expenses in obese adults: a US population-based study.

Authors:  Jun Wu; Mary L Davis-Ajami; Zhiqiang K Lu
Journal:  Clinicoecon Outcomes Res       Date:  2018-12-31

8.  Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.

Authors:  Messoud Ashina; Joshua M Cohen; Sanjay K Gandhi; Evelyn Du
Journal:  Headache       Date:  2021-06-11       Impact factor: 5.887

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.